Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06928753 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana

Study acronym: CHIK-RE-VAC
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later Apr 2026 → Jun 2027
Enrollment reduced 16% 1800 → 1505 participants
See other at-risk trials from Centre Hospitalier Universitaire de la Réunion

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 12 words
    • Collaborators revised (7)
  2. Primary completion pushed from Apr 2026 to Jun 2027v4 Show 7 more changesShow less
    • Enrollment reduced: 1800 → 1505 participants
    • Study completion pushed from Oct 2026 to Dec 2027
    • Interventions modified
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 77 words
    • Collaborators: 4 to 7
    • Study title shortened, about 7 words
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2025 to Apr 18, 2025
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and immunogenicity of the recommended vaccines, IXCHIQ® and VIMKUNYA®, as defined by the French National Authority for Health (HAS).
Trial Details
NCT Number NCT06928753
Lead Sponsor Centre Hospitalier Universitaire de la Réunion
Collaborators: ANRS, Emerging Infectious Diseases, ARS La Réunion, Direction Générale de l'Offre de Soins, Valneva Austria GmbH, Bavarian Nordic, Agence Régionale de Santé Guyane, Région Réunion
Conditions
(from sponsor)		 Chikungunya Virus Infection
Related terms Chikungunya Fever
Enrollment 1,505 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov